Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher vs. Lower Dose Heparin for PCI
NCT04049591Recruiting
- Sponsor
- Population Health Research Institute
- Start
- Mar 2022
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in coronary artery disease (CAD) (2 arms), sponsored by Population Health Research Institute. Primary endpoint: Composite of death, myocardial infarction, or target vessel revascularization at 30 days. Started Mar 2022; status: recruiting.
02
Drugs
heparin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04049591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049591.